OSMAN ÇAĞLAYAN, Biltan ERSÖZ, Gülriz MENTEŞ, Necla OSMANOĞLU

Gastrointestinal malignitelerde fukoz ve fukozidaz

Amaç: Serum glikoproteinlerindeki değişimler malignitelerde karakteristiktir. Son zamanlarda protein bağlı karbonhidratlar kanserde glikoprotein seviyesinin bir göstergesi olarak incelenmektedir. Bu çalışmada, gastrointestinal malignitelerde, L-fukoz ile onun enzimi a-L-fukozidaz’daki değişimleri incelemek amaçlanmıştır. Yöntem: Kontrol (n=20), siroz (n=20) ve gastrointestinal malignite (n=20) gruplarının Proteine bağlı fukoz (PBF) değerleri Dische ve Shettles’in yöntemiyle tayin edildi. M fraksiyonu için Tatsumura’nın ekstraksiyon yöntemi uygulandı. G fraksiyonu totalden M çıkarılarak hesaplandı. a-L-fukozidaz aktivitesi 37 oC’de 1 saatte parçalanan p-nitrofenil a-L-fukozid’in 1 ml’de nanomol cinsinden miktarı şeklinde belirlendi. Total protein biüret yöntemiyle ölçüldü. Bulgular: PBF değerleri kontrol, siroz ve malignite gruplarında sırasıyla 7.33±1.36, 13.16±2.88 ve 14.53±3.25 mg/dl; a-L-fukozidaz değerleri 319.2±99.5, 463.6±215.9 ve 528.5±347.3 nmol/ml/saat idi. Total fukoz, G ve M fraksiyonları, fukoz/protein oranı ve a-L-fukozidaz malign grupta, kontrol grubuna göre anlamlı şekilde yüksekti (fukozidaz için p

Fucose and fucosidase in gastrointestinal malignancies

Objective: Recently, protein bound carbohydrates have been investigated as indexes of glycoprotein levels in cancer. This study investigates the changes in L-fucose, and its enzyme a-L-fucosidase in gastrointestinal malignancies. Methods: In the control (n=20), cirrhotic (n=20) and gastrointestinal malignancy (n=20) groups, protein bound fucose (PBF) was determined by the Dische and Shettles technique. For its M fraction, the Tatsumura extraction procedure was applied. The G fraction was estimated by subtracting M from total. a-L-fucosidase was estimated as nanomoles of p-nitrophenyl a-L-fucoside, cleaved per ml of serum, per hour at 37 oC. Results: PBF was 7.33±1.36, 13.16±2.88 and 14.53±3.25 mg/dl, a-L-fucosidase was 319.2±99.5, 463.6±215.9 and 528.5±347.3 nmol/ml/h in the control, cirrhotic and malignant groups, respectively. Total fucose, its G and M fractions, fucose/protein ratio and a-L-fucosidase were significantly higher in the malignant group compared to the controls (for the fucosidase p<0.02, for the others p<0.001). However, in the malignant group compared to the cirrhotics, only the total fucose/protein ratio was significantly higher (p<0.05). Satisfactory results (all above 70% ) related to sensitivity, specificity and diagnostic accuracy were also obtained. Conclusion: We conclude that a-L-fucosidase and especially fucose are promising tumor markers in establishing gastrointestinal malignancies. These findings may be a stimulus for further research of fucose metabolism in malignancy.

PDF

___

Yogeeswaran G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983;38:289-350
Bradley WP, Blasco AP, Weiss JF, Alexander JC, Silverman NA, Chretien PB. Correlations among serum protein bound carbohydrates, serum glycoproteins, lymphocyte reactivity and tumor burden in cancer patients. Cancer 1977;40:2264-72.
Macbeth RAL, Bekesi JG. Plasma glycoproteins in various disease states including carcinoma. Cancer Res 1962;22:1170-6.
Nigam VN, Cantero A. Polysaccharides in cancer: Glycoproteins and glycolipids. Adv Cancer Res 1973;17:1-80.
Turner GA, Skillen AW, Buamah P, Guthrie D, Welsh J, Harrison J, et al. Relation between raised concentrations of fucose, sialic acid and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers. J Clin Pathol 1985;38:588-92.
Bhuvarahamurthy V, Balasubramanian N, Vijayakumar S, Govindasamy S. Effect of radiation on serum glycoproteins and glycosidases in patients with cervical carcinoma. Int J Gynaecol Obstet 1995;48:49-54.
Patel PS, Adhvaryu SG, Balar DB, Parikh BJ, Shah PM. Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias. Anticancer Res 1994;14(2B):747-51.
Jass JR, Allison LJ, Stewart SM, Lane MR. Ulex europaeus agglutinin-1 binding in hereditary bowel cancer. Pathology 1993;25:114-9.
Barlow JJ, Dillard PH. Serum protein bound fucose in patients with gynecologic cancers. Obstet Gynecol 1972;39:727-34.
Evans AS, Dolan MF, Sobocinski PZ, Quinn FA. Utility of serum protein bound neutral hexoses and L-fucose for estimation of malignant tumor extension and evaluation of efficacy of therapy. Cancer Res 1974;34:538-42.
Hadjivassilou A, Castanaki A, Hristou G, Lissaios B. The diagnostic value of protein bound serum fucose in cancer of the brest. Surg Gynec Obst 1975;140:239-40.
Klishevich IB. Serum albumin fucose in cancer patients. Vopr Onkol 1982;28:38-40.
Marth E, Flaschka G, Stiegler S, Möse JR. Sialic acid as a marker for differentiation between benign and malignant intracranial tumors. Clin Chim Acta 1988;176:251-8.
Rosato FE, Seltzer MH. Serum protein bound fucose and carcinoma of the female breast. Am J Surg 1969;118:61-4.
Rosato FE. Serum glycoproteins in the evaluation of breast cancer. Surg Gynec Obst 1967;124:1291-4.
Rosato FE. Glycoproteins in mammary cancer. Ann Surg 1968;168:818-20.
Tatsumura T, Sato H, Mori A, Komori Y, Yamamoto K, Fukatani G, et al. Clinical significance of fucose level in glycoprotein fraction of serum in patients with malignant tumors. Cancer Res 1977;37:4101-3.
Voigtmann R, Pokorny J, Meinshausen MS, Meinshausen A. Evaluation and limitations of the lipid associated sialic acid test for the detection of human cancer. Cancer 1989;64:2279-83.
Troost J, Heijden MCM, Staal GEJ. Characterization of a-L-fucosidase from two different families with fucosidosis. Clin Chim Acta 1976;73:329-46.
Gil-Martin E, Gil-Seijo S, Nieto-Novoa C, Fernandez-Briera A. Elevation of acid glycosidase activities in thyroid and gastric tumors. Int J Biochem Cell Biol 1996;28:651-7.
Wang JW, Ambros RA, Weber PB, Rosano TG. Fucosyltransferase and alpha-L-fucosidase activities and fucose levels in normal and malignant endometrial tissue. Cancer Res 1995;55:3654-8.
Giardina MG, Matarazzo M, Varriale A, Morante R, Napoli A, Martino R. Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 1992;70:1044-8.
Lopez VJ. Value of serum measurement of alpha-L-fucosidase in the diagnosis of hepatocarcinoma. Med Clin (Barc) 1989;93:241-3.
Zielke K, Okada S, O’Brien JS. Fucosidosis: Diagnosis by serum assay of a-L-fucosidase. J Lab Clin Med 1972;79:164-9.
Turner GA, Goodarzi MT, Thompson S. Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconj J 1995;12:211-8.
Goodarzi MT, Turner GA. Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. Clin Chim Acta 1995;236:161-71.
Bukofzer S, Stass PM, Kew MC, Beer M, Groeneveld HT. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. Br J Cancer 1989;59:417-20.
Calvo P, Barba JL, Cabezas JA. Serum b-N-acetylglucos-aminidase, b-D-glucosidase, a-D-glucosidase, b-D-fucosidase, a-L-fucosidase and b-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer. Clin Chim Acta 1982;119:15-9.
Faber CN, Glew RH, Stanko RT. Serum alpha mannosidase in patients with alcoholic liver disease. Enzyme 1984;31:1-10.
Shen W, Shen DM. A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma. Chung Hua Nei Ko Tsa Chih 1989;28:397-9.
Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M, et al. Serum a-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology 1984;4:889-92.
Yu ZW, Duan FL, Yang XW. Diagnostic significance of the determination of serum alpha-L-fucosidase in primary hepatocellular carcinoma. Chung Hua Nei Ko Tsa Chih 1988;28:394-6.
Hutchinson WL, Johnson PJ, Du MQ, Williams R. Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci 1991;81:177-82.
Zheng T, Ren ZY. Activities of serum enzymes in patients with viral hepatitis B, posthepatitic cirrhosis and hepatocellular carcinoma. Chin Med J 1990;103:729-34.
Reglero A, Carretero MI, Cabezas JA. Increased serum alpha-L-fucosidase and beta-N-acetylglucosaminidase activities in diabetic, cirrhotic and gastric cancer patients. Clin Chim Acta 1980;103:155-8.
Chester MA, Hultberg B, Sjöblad S. A comparison of the a-L-fucosidase activities of human liver and serum. Biochim Biophys Acta 1977;485:147-55.